Soni N, Ora M, Jena A, Rana P, Mangla R, Ellika S, et al. Amino acid tracer PET MRI in glioma management: what a neuroradiologist needs to know. AJNR Am J Neuroradiol. 2023;44:236–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bolcaen J, Kleynhans J, Nair S, Verhoeven J, Goethals I, Sathekge M, et al. A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma. Theranostics. 2021;11:7911–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Halloran PJ, Viel T, Murray DW, Wachsmuth L, Schwegmann K, Wagner S, et al. Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers. Eur J Nucl Med Mol Imaging. 2016;43:1673–83.

Article  PubMed  Google Scholar 

Celli M, Caroli P, Amadori E, Arpa D, Gurrieri L, Ghigi G, et al. Diagnostic and prognostic potential of (18)F-FET PET in the differential diagnosis of glioma recurrence and treatment-induced changes after chemoradiation therapy. Front Oncol. 2021;11:721821.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hutterer M, Nowosielski M, Putzer D, Jansen NL, Seiz M, Schocke M, et al. [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro-Oncol. 2013;15:341–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Verger A, Stoffels G, Bauer EK, Lohmann P, Blau T, Fink GR, et al. Static and dynamic (18)F-FET PET for the characterization of gliomas defined by IDH and 1p/19q status. Eur J Nucl Med Mol Imaging. 2018;45:443–51.

Article  CAS  PubMed  Google Scholar 

Li Z, Kaiser L, Holzgreve A, Ruf VC, Suchorska B, Wenter V, et al. Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [(18)F]FET PET radiomics. Eur J Nucl Med Mol Imaging. 2021;48:4415–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Furtak J, Rakowska J, Szylberg T, Harat M, Malkowski B, Harat M. Glioma biopsy based on hybrid dual time-point FET-PET/MRI-A proof of concept study. Front Neurol. 2021;12:634609.

Article  PubMed  PubMed Central  Google Scholar 

Kaiser L, Quach S, Zounek AJ, Wiestler B, Zatcepin A, Holzgreve A, et al. Enhancing predictability of IDH mutation status in glioma patients at initial diagnosis: a comparative analysis of radiomics from MRI, [(18)F]FET PET, and TSPO PET. Eur J Nucl Med Mol Imaging. 2024;51:2371–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harat M, Rakowska J, Harat M, Szylberg T, Furtak J, Miechowicz I, et al. Combining amino acid PET and MRI imaging increases accuracy to define malignant areas in adult glioma. Nat Commun. 2023;14:4572.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the Central Nervous System: a summary. Neuro-Oncol. 2021;23:1231–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Johnson DR, Giannini C, Vaubel RA, Morris JM, Eckel LJ, Kaufmann TJ, et al. A radiologist’s guide to the 2021 WHO central nervous system tumor classification: part I-key concepts and the spectrum of diffuse gliomas. Radiology. 2022;304:494–508.

Article  PubMed  Google Scholar 

Park YW, Vollmuth P, Foltyn-Dumitru M, Sahm F, Ahn SS, Chang JH, et al. The 2021 WHO classification for gliomas and implications on imaging diagnosis: part 1-key points of the fifth edition and summary of imaging findings on adult-type diffuse gliomas. J Magn Reson Imaging. 2023;58:677–89.

Article  PubMed  Google Scholar 

Friedrich M, Sankowski R, Bunse L, Kilian M, Green E, Guevara CR, et al. Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas. Nat Cancer. 2021;2:723–40.

Article  CAS  PubMed  Google Scholar 

An S, Lu X, Zhao W, Sun T, Zhang Y, Lu Y, et al. Amino acid metabolism abnormity and microenvironment variation mediated Targeting and Controlled Glioma Chemotherapy. Small. 2016;12:5633–45.

Article  CAS  PubMed  Google Scholar 

Cappoli N, Jenkinson MD, Russo CD, Dickens D. LAT1, a novel pharmacological target for the treatment of glioblastoma. Biochem Pharmacol. 2022;201:115103.

Article  CAS  PubMed  Google Scholar 

Park H, Chun SM, Shim J, Oh JH, Cho EJ, Hwang HS, et al. Detection of chromosome structural variation by targeted next-generation sequencing and a deep learning application. Sci Rep. 2019;9:3644.

Article  PubMed  PubMed Central  Google Scholar 

Kim JH, Yoon S, Lee DH, Jang SJ, Chun SM, Kim SW. Real-world utility of next-generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma. Cancer Med. 2021;10:3197–204.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Unterrainer M, Vettermann F, Brendel M, Holzgreve A, Lifschitz M, Zahringer M, et al. Towards standardization of (18)F-FET PET imaging: do we need a consistent method of background activity assessment? EJNMMI Res. 2017;7:48.

Article  PubMed  PubMed Central  Google Scholar 

Karschnia P, Dietrich J, Bruno F, Dono A, Juenget ST, Teske N, et al. Surgical management and outcome of newly diagnosed glioblastoma without contrast enhancement (low-grade appearance): a report of the RANO resect group. Neuro-Oncol. 2024;26:166–77.

Article  PubMed  Google Scholar 

Kiviniemi A, Gardberg M, Ek P, Frantzen J, Bobacka J, Minn H. Gadolinium retention in gliomas and adjacent normal brain tissue: association with tumor contrast enhancement and linear/macrocyclic agents. Neuroradiology. 2019;61:535–44.

Article  PubMed  Google Scholar 

Albert NL, Galldiks N, Ellingson BM, van den Bent MJ, Chang SM, Cicone F, et al. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group. Lancet Oncol. 2024;25:e29–41.

Article  PubMed  Google Scholar 

Lohmeier J, Radbruch H, Brenner W, Hamm B, Tietze A, Makowski MR. Predictive IDH genotyping based on the evaluation of spatial metabolic heterogeneity by compartmental uptake characteristics in preoperative glioma using (18)F-FET PET. J Nucl Med. 2023;64:1683–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A. 2006;103:1475–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Appay R, Dehais C, Maurage CA, Alentorn A, Carpentier C, Colin C, et al. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro-Oncol. 2019;21:1519–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maragkou T, Reinhard S, Jungo P, Pasquier B, Neuenschwander M, Schucht P, et al. Evaluation of MTAP and p16 immunohistochemical deficiency as surrogate marker for CDKN2A/B homozygous deletion in gliomas. Pathology. 2023;55:466–77.

Article  CAS  PubMed  Google Scholar 

Tanaka S, Batchelor TT, Iafrate AJ, Dias-Santagata D, Borger DR, Ellisen LW, et al. PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma. Acta Neuropathol Commun. 2019;7:66.

Article  PubMed  PubMed Central  Google Scholar 

Ma S, Rudra S, Campian JL, Dahiya S, Dunn GP, Johanns T, et al. Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma. Neurooncol Adv. 2020;2:vdaa126.

PubMed  PubMed Central  Google Scholar 

Kunz M, Thon N, Eigenbrod S, Hartmann C, Egensperger R, Herms J, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro-Oncol. 2011;13:307–16.

Article  CAS